Iovance: The Company Makes It Hard To Estimate Revenue Growth
Source: SeekingAlpha
2025-03-18 12:02:56 ET
Summary
- Iovance reported Q4'24 revenues of $25M from Proleukin, a 51% increase from the prior quarter, but Amtagvi revenues of 48.7M, were up just 16% from the prior quarter.
- Proleukin revenues could be a leading indicator for Amtagvi revenues, but the company also supplied a new distributor in Q4'24, making it hard to judge Q1'25 Amtagvi growth.
- Obsidian Therapeutics represents a relevant competitor with a cell therapy called OBX-115, that has potential advantages over lifileucel, although IOVA has its own next-gen therapies in development.
Read the full article on Seeking Alpha
For further details see:
Iovance: The Company Makes It Hard To Estimate Revenue Growth
Replimune Group Inc.
NASDAQ: REPL
REPL Trading
12.06% G/L:
$5.21 Last:
941,552 Volume:
$4.90 Open:
REPL Latest News
REPL Stock Data
$646,543,607
51,607,887
0.33%
61
N/A
Biotechnology & Life Sciences
Healthcare
US
Woburn
